Protara Therapeutics, Inc. — Director's Dealing 2016

Jun 7, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PROTEON THERAPEUTICS INC (PRTO)
CIK: 0001359931
Period of Report: 2016-06-06

Reporting Person: Eldridge, George Arthur (Sr VP, CFO, Treasurer, Sec.)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-06-06	Common Stock	P	2750	$5.78	Acquired	2750	Direct
2016-06-06	Common Stock	P	425	$5.76	Acquired	425	Indirect
2016-06-06	Common Stock	P	425	$5.776	Acquired	425	Indirect
2016-06-06	Common Stock	P	400	$5.78	Acquired	400	Indirect

Footnotes

F1: The purchase price of $5.78 is reflective of the weighted average purchase price of all transactions reported on this line. The prices for the transactions reported on this line range from $5.78 to $5.79. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

F2: These securities were purchased by the reporting person as custodian for three minor children under the Uniform Transfers to Minors Act. The reporting person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose.